{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:50:07Z","timestamp":1762660207366,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.cllc.2022.04.002","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T07:53:26Z","timestamp":1651305206000},"page":"410-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6522-6033","authenticated-orcid":false,"given":"Vichitra","family":"Behel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Chougule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanita","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay Maruti","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandini","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajaykumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Chopade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srushti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sucheta","family":"More","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shripad Dinanath","family":"Banavali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratik","family":"Chandrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.04.002_bib0001","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/CRST.CRST_51_19","article-title":"Epidermal growth factor receptor-mutated non-small-cell lung cancer: a primer on contemporary management","volume":"2","author":"Rajendra","year":"2019","journal-title":"Cancer Res, Stats, and Treatment"},{"key":"10.1016\/j.cllc.2022.04.002_bib0002","unstructured":"Lilenbaum RC. Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer. UpToDate. Waltham, MA. UpToDate Inc. Accessed April 6, 2022. Available at: https:\/\/www.uptodate.com."},{"key":"10.1016\/j.cllc.2022.04.002_bib0003","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.cllc.2022.04.002_bib0004","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.04.002_bib0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mdy554","article-title":"Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS","volume":"30","author":"Wu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.04.002_bib0006","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/10408363.2017.1299683","article-title":"Using circulating cell-free DNA to monitor personalized cancer therapy","volume":"54","author":"Oellerich","year":"2017","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.cllc.2022.04.002_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-015-0193-6","article-title":"Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer","volume":"8","author":"Sun","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.cllc.2022.04.002_bib0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2012.43.1718","article-title":"Use of research biopsies in clinical trials: are risks and benefits adequately discussed?","volume":"31","author":"Overman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.04.002_bib0009","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.04.002_bib0010","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.04.002_bib0011","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2022.04.002_bib0012","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-14-2594","article-title":"Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy","volume":"21","author":"Mok","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.04.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cllc.2022.04.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cllc.2022.04.002_bib0015","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1373\/clinchem.2015.253476","article-title":"Sequencing circulating cell-free DNA: the potential to refine precision cancer medicine","volume":"62","author":"Tie","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.cllc.2022.04.002_bib0016","doi-asserted-by":"crossref","first-page":"e61561","DOI":"10.1371\/journal.pone.0061561","article-title":"EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy","volume":"8","author":"Noronha","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2022.04.002_bib0017","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"Lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.cllc.2022.04.002_bib0018","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1634\/theoncologist.2016-0082","article-title":"Clinical utility of liquid diagnostic platforms in non-small cell lung cancer","volume":"21","author":"Levy","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2022.04.002_bib0019","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/JTO.0000000000000443","article-title":"Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma","volume":"10","author":"Tseng","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.04.002_bib0020","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2217\/fon.15.23","article-title":"EGFR mutations in lung cancer: from tissue testing to liquid biopsy","volume":"11","author":"Fenizia","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.cllc.2022.04.002_bib0021","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.csbj.2018.10.002","article-title":"Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management","volume":"16","author":"Elazezy","year":"2018","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.cllc.2022.04.002_bib0022","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.3390\/cancers12123804","article-title":"Next generation sequencing-based profiling of cell free DNA in patients with advanced non-small cell lung cancer: advantages and pitfalls","volume":"12","author":"Esposito Abate","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.cllc.2022.04.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194630","article-title":"Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA","volume":"13","author":"Gale","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.cllc.2022.04.002_bib0024","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/annonc\/mdv177","article-title":"Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer","volume":"26","author":"Tie","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.04.002_bib0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-319-42044-8_34","article-title":"Detection and quantification of KIT mutations in ctDNA by plasma safe-SeqS","volume":"924","author":"Fredebohm","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.cllc.2022.04.002_bib0026","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1373\/clinchem.2015.241414","article-title":"Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA","volume":"61","author":"Uchida","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.cllc.2022.04.002_bib0027","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3390\/ph14060596","article-title":"cfDNA Sequencing: Technological approaches and bioinformatic issues","volume":"14","author":"Bohers","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cllc.2022.04.002_bib0028","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/JTO.0000000000000643","article-title":"Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients","volume":"10","author":"Marchetti","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.04.002_bib0029","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3390\/diagnostics11081319","article-title":"Technical evaluation of the COBAS EGFR Semiquantitative Index (SQI) for plasma cfDNA testing in NSCLC patients with EGFR Exon 19 Deletions","volume":"11","author":"Gonz\u00e1lez de Aledo-Castillo","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.cllc.2022.04.002_bib0030","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-15-1260","article-title":"Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686)","volume":"22","author":"Karlovich","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.04.002_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-294","article-title":"Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays","volume":"14","author":"Weber","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2022.04.002_bib0032","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jmoldx.2018.03.006","article-title":"Detection of EGFR variants in plasma: a multilaboratory comparison of a real-time PCR EGFR mutation test in Europe","volume":"20","author":"Keppens","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.cllc.2022.04.002_bib0033","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","article-title":"Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)","volume":"26","author":"Zhou","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422000638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422000638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:12:17Z","timestamp":1761505937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422000638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1525730422000638"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.04.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}